1,391 Shares in Axon Enterprise, Inc $AXON Acquired by ZEGA Investments LLC

ZEGA Investments LLC acquired a new stake in Axon Enterprise, Inc (NASDAQ:AXON) in the 3rd quarter, HoldingsChannel reports. The institutional investor acquired 1,391 shares of the biotechnology company’s stock, valued at approximately $998,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Stone House Investment Management LLC purchased a new stake in shares of Axon Enterprise during the third quarter worth $29,000. Hemington Wealth Management grew its holdings in Axon Enterprise by 70.8% in the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 17 shares in the last quarter. Whipplewood Advisors LLC raised its stake in Axon Enterprise by 192.9% during the second quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 27 shares during the period. Darwin Wealth Management LLC acquired a new position in Axon Enterprise in the 2nd quarter valued at about $37,000. Finally, NewSquare Capital LLC boosted its holdings in Axon Enterprise by 96.2% in the 2nd quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 25 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on AXON shares. The Goldman Sachs Group cut their price target on shares of Axon Enterprise from $940.00 to $800.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Cowen reiterated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Barclays reduced their price target on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Wall Street Zen downgraded shares of Axon Enterprise from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, UBS Group decreased their price target on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. Fourteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $805.71.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $631.73 on Tuesday. Axon Enterprise, Inc has a 52 week low of $469.24 and a 52 week high of $885.91. The company has a fifty day simple moving average of $571.01 and a two-hundred day simple moving average of $686.17. The company has a quick ratio of 2.89, a current ratio of 3.12 and a debt-to-equity ratio of 0.57. The company has a market cap of $49.85 billion, a price-to-earnings ratio of 199.92, a price-to-earnings-growth ratio of 19.89 and a beta of 1.41.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.46). The company had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The firm’s revenue was up 30.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.45 earnings per share. As a group, equities analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Jeffrey C. Kunins sold 1,797 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $539.23, for a total transaction of $968,996.31. Following the sale, the insider directly owned 83,485 shares in the company, valued at approximately $45,017,616.55. This represents a 2.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Jennifer H. Mak sold 1,134 shares of the firm’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $600.00, for a total transaction of $680,400.00. Following the completion of the sale, the chief accounting officer owned 13,740 shares in the company, valued at $8,244,000. The trade was a 7.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 60,540 shares of company stock worth $34,684,738. Corporate insiders own 5.70% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.